HCoV-NL63 and HCoV-HKU1 seroprevalence and its relationship with the clinical features of COVID-19 patients from Villavicencio, Colombia
To our knowledge, this is the first study addressing seroprevalence of HCoV IgG antibodies in Colombia and Latin America. Previous exposure to HCoV-NL63 could protect against severe COVID-19, whereas patients with underlying HCoV-NL63 and HCoVHKU1 coinfection could be hospitalized with severe signs of COVID-19.
Authors
- Lida Carolina Lesmes-Rodríguez (ORCID: https://orcid.org/0000-0002-1312-0891)
- Dumar Alexander Jaramillo Hernández (ORCID: https://orcid.org/0000-0003-1377-1747)
- Luz Natalia Pedraza Castillo (ORCID: https://orcid.org/0000-0001-5991-0525)
Institutions
- Universidad de los Llanos (CO)
Publication Details
- Journal
- Biomédica
- Published
- 2024-08-29
- DOI
- https://doi.org/10.7705/biomedica.7168
- Citations
- 1
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 0.39
Funders
- Universidad de los Llanos